• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
LIU Yingying,WANG Guixia,LI Zhenhe,LIU Chong,SUN Jun,GUO Zhao'an,CHEN Daquan,WANG Xiaona,ZHEN Guodong.Effect of Yishen Huashi Granules in protecting podocytes andimproving diabetic kidney disease[J].Journal Of Pharmaceutical Research,2025,44(10):950-954[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 1999times   Download 725次 QR Code for this article
Scan with your phone!
益肾化湿颗粒保护足细胞改善糖尿病肾病的作用
刘迎迎1,王贵霞2,李振翮2,刘充3,孙珺3,郭兆安1,陈大全4,王晓娜1,甄国栋2
Font:Larger+|Default|Smaller-
(1.山东中医药大学附属医院,山东 济南 250014;2.临沂市中心医院,山东 沂水 276400;3.威海市中医院,山东 威海 264200;4.潍坊市中医药产业技术研究院,山东 潍坊 261100)
摘要:
目的 研究益肾化湿颗粒治疗糖尿病肾脏疾病(DKD)的疗效,探讨可能的作用机制。方法 选用雄性SD大鼠50只,随机选取10只为空白对照组。其余大鼠利用高脂高糖饲料联合腹腔注射STZ建立DKD大鼠模型,随机分为模型组、缬沙坦组和益肾化湿颗粒组(YSHS组)。给药8周,监测治疗期间大鼠血糖,观察治疗前后大鼠血脂和肾功能、肾脏组织病理尤其是足细胞的病理改变。结果 与缬沙坦组相比,给药8周后,YSHS组血糖显著降低,有统计学差异(P<0.01);YSHS组、缬沙坦组的SCr、BUN、24hUP较模型组均降低(P<0.05),YSHS组与缬沙坦组间无明显差异(P>0.05)。与缬沙坦组相比,YSHS组LDL-C明显降低(P<0.01)。肾脏病理显示光镜下YSHS组、缬沙坦组肾脏病理损伤均较模型组有改善,YSHS组更明显;电镜下YSHS组、缬沙坦组足细胞病变较模型组均有所改善,YSHS组更明显。结论 益肾化湿颗粒对血糖的调节作用优于缬沙坦,保护肾功能、降低尿蛋白的作用与缬沙坦相当。其对足细胞的保护作用可能是作用机制之一。
关键词:  益肾化湿颗粒  糖尿病肾病  足细胞  实验研究
DOI:10.13506/j.cnki.jpr.2025.10.003
基金项目:中国中西医结合学会益肾化湿颗粒临床应用研究和基础研究开发课题;山东中医药大学附属医院“青年名中医”项目
Publication Date:October 25, 2025
Effect of Yishen Huashi Granules in protecting podocytes andimproving diabetic kidney disease
LIU Yingying1,WANG Guixia2,LI Zhenhe2,LIU Chong3,SUN Jun3,GUO Zhao'an1,CHEN Daquan4,WANG Xiaona1,ZHEN Guodong2
(1.Linyi Central Hospital,Yishui 276400,China;2.Weihai Hospital of Traditional Chinese Medicine,Weihai 264200,China;3.Affiliated Hospital of Shandong University of Traditional Chinese Medicine,Jinan 250014,China;4.Weifang Traditional Chinese Medicine Industry Technology Research Institute,Weifang 261100,China)
Abstract:
Objective To study the therapeutic effect of Yishen Huashi Granules on diabetic kidney disease (DKD) , and to explore the possible mechanism. Methods Fifty male SD rats were selected, and 10 were randomly selected as blank control group. The other rats were treated with high-fat and high-sugar diet combined with intraperitoneal injection of STZ to establish DKD rat model, and were randomly divided into model group, valsartan group and Yishen Huashi Granules group (YSHS group). After 8 weeks of administration, the blood glucose of rats was monitored during treatment, and the changes of blood lipid, renal function, renal histopathology, especially podocytes were observed before and after treatment.Results Compared with valsartan group, after 8 weeks of administration, blood glucose in YSHS group was significantly decreased, with statistical difference (P<0.01); SCr, BUN and 24hUP in YSHS group and valsartan group were lower than those in model group (P<0.05), but there was no significant difference between YSHS group and valsartan group (P>0.05). Compared with valsartan group, LDL-C in YSHS group was significantly decreased (P<0.01). Renal pathology showed that renal pathological injury in YSHS group and valsartan group was improved compared with model group under light microscope, and YSHS group was more obvious. Under electron microscope, podocyte lesions in YSHS group and valsartan group were improved compared with model group, and YSHS group was more obvious. Conclusion The effect of Yishenhuashi Granules on blood glucose regulation is better than valsartan, and the effect of protecting renal function and reducing urinary protein is similar to valsartan. Its protective effect on podocytes may be one of the mechanisms.
Key words:  Yishen Huashi Granules  Diabetic kidney disease  Podocyte  Experimental study
Today's Visits:509    Total Visits:2383239
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.